UNC Lineberger Comprehensive Cancer Center: Lymphoma trials

The registry lists 23 Lymphoma studies with UNC Lineberger Comprehensive Cancer Center as lead sponsor. 6 are open to participants now and 7 have results posted.

Phase 1 11Phase 2 10No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramRecruitingNCT06860880Not applicable
• DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable
• Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.RecruitingNCT04223765Phase 1
• CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaRecruitingNCT04083495Phase 2
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 1Results posted
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
• Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 1Results posted
• Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaCompletedNCT01578967Not applicableResults posted
• Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT01234467Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T CellsWithdrawnNCT07071909Phase 1/2
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCLActive, not recruitingNCT03602157Phase 1
• Clinical Cohort of Lymphoma Patients in MalawiActive, not recruitingNCT02835911
• A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
• Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLActive, not recruitingNCT02690545Phase 1/2
• Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaCompletedNCT02660710Phase 2
• Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)WithdrawnNCT01316146Phase 1
• Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
• Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00334438Phase 1
• Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2